ARGX•benzinga•
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
Summary
Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga